FULGENT GENETICS DL-,0001 Logo
US3596641098
A2AS4N
FLGT

FULGENT GENETICS DL-,0001

Prognose

Analytikernes gennemsnitlige kursmål er 17,32 € (-21,27 %). Medianen er 17,32 € (-21,27 %).

Køb
  6
Behold
  3
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Fulgent: phase‑2 data on cancer drug FID‑007 show 60% response rate

    Fulgent published an abstract of the open‑label, randomized phase‑2 study of FID‑007 in combination with cetuximab, which will be presented at the ASCO meeting on June 1, 2026. Among 42 evaluable patients with recurrent/metastatic head and neck squamous cell carcinoma, the objective response rate was 60% and median progression‑free survival was 7.2 months; median duration of response was 7.4 months. The safety profile consisted mostly of grade‑1/2 events; grade‑3/4 events included neutropenia and anemia, and in arm B a treatment‑related death due to pneumonia was reported. According to the analysis, Fulgent has more liquid assets than liabilities, but the stock has fallen 45% over the past six months and is considered undervalued. » Mere på de.investing.com


  • Fulgent misses Q1 revenue forecast after customer loss, positive FID‑007 data give hope

    Fulgent reported Q1 2026 revenue of $71.1 million and a loss per share of $0.36, both well below analyst expectations; the company attributed the decline mainly to its largest customer moving to internal capacities. Despite margin pressure and negative operating cash flow, strong Phase‑2 data for FID‑007 stood out (ORR 51%, median PFS 7.8 months), and management plans an FDA meeting and the preparation of a Phase‑3 protocol. Fulgent maintains its full‑year guidance of $350 million, emphasizes its liquid balance sheet and is banking on recent acquisitions and the therapeutic pipeline, but must overcome cash burn, margin pressure and stabilize revenue. » Mere på de.investing.com


  • Fulgent reports Q4 results: stock falls after departure of major customer

    Fulgent reported Q4/2025 revenue of $83m (below expectations) and surprised with non‑GAAP EPS of $0.16. The stock plunged about 22% in premarket trading after it emerged that the largest customer (22% of 2025 revenue) will bring testing in‑house. The company forecasts 2026 revenue of $350m and a non‑GAAP loss per share of ($1.45), but expects strong headwinds through mid‑2026. Fulgent highlights a strong balance sheet ($336.1m in cash and marketable securities as of 12/31/2025) and progress in its therapeutic pipeline around FID‑007 as a long‑term value driver. » Mere på de.investing.com


  • Fulgent Genetics raises full-year revenue forecast after strong quarter

    Fulgent Genetics reported first-quarter revenue of $84.1 million, beating expectations. The company raised its full-year forecast to $325 million and reported improved non-GAAP gross margins in the mid-40% range. Cash on hand is expected to be around $800 million by the end of 2025 to fund investments in technology, M&A and therapeutics; significantly higher therapeutics spending is planned for 2026 and the start of a Phase 3 trial is expected. Operationally, Fulgent is focusing on efficiency gains, expanding sales and broadening biopharma services, while partnerships are developing more slowly than expected. » Mere på de.investing.com


  • Fulgent Genetics: positive phase-2 data in head and neck cancer

    Fulgent Genetics reported preliminary phase-2 data for FID-007 in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma. Among 35 evaluable patients the objective response rate was 51% (44% at 75 mg/m², 59% at 125 mg/m²) and median progression-free survival was 7.8 months versus a historical 2.3 months. The treatment showed a favorable safety profile with 6% serious treatment-related adverse events; common grade-3 events were lymphopenia (19%), neutropenia (17%) and anemia (8%). Fulgent also has a solid balance sheet, reported Q2 revenue of $81.8m above expectations and received an upgrade from UBS with a price target raised to $30.00. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde FULGENT GENETICS DL-,0001 en omsætning på 79,82 mio. € og et nettoresultat på -11,61 mio. €

(EUR) september 2026
YoY
Omsætning 79,82 mio. 11,42 %
Bruttofortjeneste 28,2 mio. 6,80 %
Nettoresultat -11,61 mio. 106,21 %
EBITDA -6,37 mio. 9.614,66 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
614,15 mio. €
Antal aktier
27,94 mio.
Højeste/laveste i 52 uger
28,29 € - 12,27 €
Udbytte Nej
Beta
1,00
P/E (PE Ratio)
-7,81
PEG (PEG Ratio)
0,12
K/I (PB Ratio)
0,67
P/S (PS Ratio)
2,04

Virksomhedsprofil

Fulgent Genetics, Inc. tilbyder sammen med sine datterselskaber COVID-19-, molekylær diagnostik- og genetiske testydelser til læger og patienter i USA og internationalt. Virksomheden tilbyder genetiske tests, herunder Focus- og Comprehensive-onkologipanelertests; Beacon-bærerscreeningspanelertest for arvelige tilstande; molekylær profilering af solide tumorer til testning for somatisk kræft; hurtig helgenomtestning for børn i NICU og PICU; et nyfødt genetisk analysepanel; en enkelt førstelinjetest til at påvise ataksirelaterede varianter og gentagelsesudvidelser via sekventering; picture genetics, en genetisk test initieret af patienten; whole exome- og clinical exome-paneltests; helgenom-, mutations- og gentagelsesudvidelsestestydelser samt forskningsydelsestests. Den tilbyder også næste generations sekventering og reverse transcription polymerase chain reaction-baserede tests samt antigenbaserede diagnostiske tests til påvisning af SARS-CoV-2. Derudover tilbyder virksomheden flowcytometri, en celleanalyseteknik, der giver diagnose, prognose og overvågning af maligne sygdomme; fluorescens in-situ hybridisering til at påvise og lokalisere en bestemt DNA-sekvens på et kromosom; immunhistokemi, en billeddannelsesteknik, der bruges til at visualisere antigener i celler; cytogenetik, som analyserer kromosomsættet for numeriske og strukturelle afvigelser; og molekylær testning, der omfatter hæmatopoietiske og solide tumor-molekylære assays. Virksomheden betjener forsikringsselskaber, hospitaler, medicinske institutioner, andre laboratorier, statslige organer, betalere, kommuner og store virksomheder samt patienter. Fulgent Genetics har et strategisk partnerskab med Helio Health, Inc. om at kommercialisere blodbaserede tests til tidlig kræftopsporing. Virksomheden var tidligere kendt som Fulgent Diagnostics, Inc. og skiftede navn til Fulgent Genetics, Inc. i august 2016. Fulgent Genetics, Inc. blev grundlagt i 2011 og har hovedkontor i Temple City, Californien.

Navn
FULGENT GENETICS DL-,0001
CEO
Ming Hsieh
Hjemsted El Monte, ca
USA
Websted
Sektor
Sundhed
Branche
Sundhedsudbydere og -tjenester
Børsnotering
29.09.2016
Medarbejdere 1.315

Tickersymboler

Børs Symbol
NASDAQ
FLGT
Frankfurt
7F0.F
Düsseldorf
7F0.DU
München
7F0.MU
🍪

Parqet  bruger cookies. Læs mere